The size of the Pancreatic Cancer Market in North America is estimated to be worth USD 1.53 billion by 2029 from USD 1.06 billion in 2024, growing at a CAGR of 7.54% during the forecast period.
The market for pancreatic cancer in North America is growing owing to the growing incidence of pancreatic cancer, growing population, and Increasing healthcare expenditure. The Significant rise in the number of people and growing concern about pancreatic cancer across the region propels the market growth. Pancreatic cancer is the 12th most frequent cancer among males and the 11th most common cancer among women globally. The most important factors that increase the risk are tobacco addiction and medical history. Also, Technological advancements in drug development for pancreatic cancer and evolving healthcare infrastructure are boosting the market growth during the forecast period. Growth in the pancreatic cancer therapy market will be driven by the introduction of drugs with novel mechanisms of action across several therapies, which are poised to meet high unmet needs in the US and 5EU. Moreover, the large number of unmet needs related to the disease attracts many multinational companies to invest in this division which is expected to expand the market growth.
In late-stage pancreatic cancer patients, premium-priced treatments have been introduced in the previous three to four years. The market growth trend in the recent past indicates a shift in market consumption from chemotherapy to targeted treatments, as well as a shift in the treatment paradigm towards personalized medicine methods. Therefore, over the projection period, kinase inhibitors, which comprise many types of pipeline medicines presently under development, are likely to be the pioneers among pipeline agents.
However, high costs associated with the treatment, Inadequate results after treatment, and adverse side effects are some of the factors restricting the market growth. The other factors, such as Difficulty in diagnosis during the early stages, Low success rates in clinical trials for cancer drugs, and limited treatment options, especially when the disease has spread to other organs or parts of the body, are the growth restraints of the market.
This research report on the North American Pancreatic Cancer Market has been segmented & sub-segmented into the following categories:
North American Pancreatic Cancer Market - By Treatment Type:
North American Pancreatic Cancer Market - By Cancer Type:
North American Pancreatic Cancer Market - By End User:
North American Pancreatic Cancer Market - By Country:
Geographically, the North American Pancreatic Cancer Market is projected to account for a rapid share during the forecast period. The market growth in the region is attributed to the increase in the incidence of patients with pancreatic cancer, increasing healthcare expenditures, and the rising number of therapies launched in the market. In addition, the major companies in the region are conducting research and development activities, and increasing investment for the development of cancer therapeutics centers is most likely to augment the market growth.
Pancreatic cancer is the fourth-largest cause of cancer-related fatalities in the United States, after lung cancer and breast cancer, and the seventh most significant cause of cancer-related global deaths, with 432,242 deaths reported in 2018. The most prevalent type of pancreatic cancer is pancreatic adenocarcinoma (PDAC), which is categorized as an exocrine pancreatic cancer and accounts for 80% of all pancreatic cancer diagnoses.
The US, however, is still expected to be the market leader in 2029, and is valued twice as much as in 2019, thus highlighting interesting market dynamics for this indication based on incidence rates, clinical approaches, and product commercialization.
The Canadian pancreatic cancer market is projected to witness a promising share and contribute to the regional market.
KEY MARKET PLAYERS:
Companies leading the North American pancreatic cancer market profiled in this report are Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., and NewLink Genetics Corp.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]